Physician profile
Andrew J Dailey
NPI 1083709893
$1,183.99
in general payments reported to CMS, 2019-2025
17 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $88.55 · 2021: $126 · 2022: $249 · 2023: $180 · 2024: $125 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.74 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $156.77 | 2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $144.18 | 2019-2023 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $128.66 | 2021-2025 | Jynarque |
| Baxter Healthcare | $121.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.20 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $88.94 | 2022-2023 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $81.53 | 2019-2020 | |
| Carlsmed, INC. | $64.06 | 2023 | Aprevo |
| Opko Pharmaceuticals, LLC | $60.93 | 2019-2021 | |
| Vifor Pharma, INC. | $59.84 | 2019-2022 | |
| Amgen INC. | $36.71 | 2019-2021 | |
| Ardelyx, INC. | $30.10 | 2023-2024 | Ibsrela |
| Highridge Medical LLC | $28.03 | 2024 | Mobi-C Plug & Fit US |
| Mallinckrodt Hospital Products INC. | $21.64 | 2024 | Terlivaz |
| Fresenius USA Marketing, INC. | $19.67 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $17.53 | 2021 | |
| Globus Medical, INC. | $15.77 | 2024 | Hedron Ia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.